A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.
about
Strategies to modulate immune responses: a new frontier for gene therapyNew developments in immunosuppressive therapy in renal transplantation.Daclizumab induction in solid organ transplantation.Clinical application of sirolimus in renal transplantation: an update.Steroid-free immunosuppression since 1999: 129 pediatric renal transplants with sustained graft and patient benefits.Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation.Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody.Calcineurin inhibitor-free immunosuppression in dual kidney transplantation from elderly donors.Sirolimus delays renal allograft recovery.Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation.Delayed graft function may not adversely affect short-term renal allograft outcome.Marked erythrocyte microcytosis under primary immunosuppression with sirolimus.Impact of initial exposure to calcineurin inhibitors on kidney graft function of patients at high risk to develop delayed graft function.
P2860
Q33713999-BFA17F76-EE77-4DBC-9077-BE88D3478A9DQ34701373-A3153996-3D44-45AE-AC96-59CE57EA4FD2Q35779394-4A39D347-BCF1-4B8C-A9FD-35370DC25D6FQ36054093-DFA82400-9EF5-46B1-8748-5D83B0D92243Q37300420-B26AC17B-C2B6-4FBB-9E65-318DCDA944A7Q43071206-8CFF26DB-1F28-47DC-9E8D-A3650154FD54Q43423598-93222445-DAC9-47BE-AD6B-A7F38578A3C7Q43823533-DB666DE3-BEC7-4AEB-902D-C0FE3BB76759Q44402534-D4C2CA73-EA64-4A17-B569-CF0052693971Q44402537-A4F5090E-C486-4CF5-92D5-68FF17BD311DQ44471177-1377677C-4C36-4B16-9B21-09F4B7439074Q46854916-B89CFEC9-3013-4ECD-AFEC-7FEDE96C534EQ46885126-AA81B92F-7AC2-48E9-B770-4339B2B9593E
P2860
A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
A calcineurin inhibitor-sparin ...... ed or impaired graft function.
@ast
A calcineurin inhibitor-sparin ...... ed or impaired graft function.
@en
A calcineurin inhibitor-sparin ...... ed or impaired graft function.
@nl
type
label
A calcineurin inhibitor-sparin ...... ed or impaired graft function.
@ast
A calcineurin inhibitor-sparin ...... ed or impaired graft function.
@en
A calcineurin inhibitor-sparin ...... ed or impaired graft function.
@nl
prefLabel
A calcineurin inhibitor-sparin ...... ed or impaired graft function.
@ast
A calcineurin inhibitor-sparin ...... ed or impaired graft function.
@en
A calcineurin inhibitor-sparin ...... ed or impaired graft function.
@nl
P2093
P1476
A calcineurin inhibitor-sparin ...... ed or impaired graft function.
@en
P2093
C E Freise
F Vincenti
H D Mahanty
J P Roberts
N L Ascher
P304
P356
10.1034/J.1399-0012.2000.140606.X
P577
2000-12-01T00:00:00Z